NEW YORK, June 19- Forest Laboratories Inc, the specialty drugmaker that counts investor Carl Icahn as a major shareholder, is among a handful of companies interested in bidding for Irish drugmaker Elan Corp Plc, two people familiar with the situation said.» Read More
NEW YORK-- Shares of drug developer Synergy Pharmaceuticals Inc. rose Friday after its chairman disclosed that he'd bought more of the company's stock. THE SPARK: In a form filed with the Securities and Exchange Commission, Gabriele Cerrone disclosed the purchase of 8,000 shares for $4.42 per share.
DUBLIN/ NEW YORK, June 14- Irish drug company Elan put itself up for sale on Friday, seeking to fend off a hostile bid by Royalty Pharma that shareholders will consider next week. "Elan Corporation... today announced that it is proceeding with a formal sale process in light of the expressions of interest received to date," the company said in a statement.
Biotech drugmaker Amgen Inc. said Thursday that the Food and Drug Administration has approved a new use for its bone drug Xgeva. The company, based in Thousand Oaks, Calif., said it now can market Xgeva for treating a rare condition, giant cell tumor of bone, when surgery isn't practical.
A unanimous Supreme Court decision barred patents on naturally occurring DNA, but analysts said the ruling did little harm to biotech companies.
CNBC's Bertha Coombs reports shares of Myriad Genetics are hitting an all-time high after the Supreme Court ruled a naturally occurring human gene cannot be patented, but upheld key DNA patents of Myriad's BRACAnalysis test.
The Supreme Court ruled a naturally occurring human gene cannot be patented, but upheld key DNA patents of Myriad's BRACAnalysis test. CNBC's Bertha Coombs reports.
A check on biotech stocks after the Supreme Court justices say naturally occurring human genes cannot be patented, with CNBC's Seema Mody.
NEW YORK-- Cancer drug developer Verastem Inc. said Thursday that its most advanced experimental treatment was awarded orphan drug status in the European Union. Verastem is studying the drug as a treatment for mesothelioma, a cancer caused by asbestos exposure.
Judge Edward Korman of the U.S. District Court in Brooklyn, New York, said the FDA proposal was "sufficient" to comply with his order to make emergency contraception widely available.
WASHINGTON-- Shares of Biogen Idec fell Wednesday after an analyst said the company's new multiple sclerosis treatment could face pricing pressure in Europe from generic drugs. Yaron Werber lowered his rating on the Massachusetts biotech company's stock to "Neutral" from "Buy."
WASHINGTON-- Shares of St. Jude Medical moved higher Wednesday after regulators unexpectedly approved two new heart devices from the company, despite ongoing safety issues at the company's plant in California. The Ellipse is an implantable defibrillator, while the Assura combines a pacemaker and a defibrillator.
LONDON, June 12- Britain is to regulate electronic cigarettes as non-prescription medicines from 2016 in an attempt to improve quality, though the country's drugs watchdog said they would still be sold in convenience stores.
*Sun Pharma to pay $550 million this year. June 12- Pfizer Inc said Teva Pharmaceuticals Industries Ltd and Sun Pharmaceutical Industries Ltd would pay $2.15 billion to settle a patent infringement lawsuit related to its acid-reflux drug Protonix.
Pfizer announced a $2.15 billion settlement from Teva Pharmaceuticals and and Sun Pharmaceutical for patent infringement on its drug Protonix.
LONDON, June 12- Britain is to regulate electronic cigarettes as non-prescription medicine from 2016 in an attempt to improve quality, though the country's drugs watchdog said they would still be sold in convenience stores.
Biogen Idec Inc.' s new multiple sclerosis treatment Tecfidera could face challenges in Europe from generic drugs that pressure its pricing and market share, according to a Citi analyst who lowered his rating on the stock.
LONDON, June 11- British drugmaker GlaxoSmithKline has fired its head of research and development in China after discovering that a study by some of its Chinese scientists contained misrepresentation of data.
NEW YORK, June 11- Royalty Pharma, pursuing a hostile $8 billion takeover of Irish drugmaker Elan Corp Plc, moved on Tuesday to make sure it is not blocked by a potential $200 million share buyback and drug spinoff at the target company.
INCLINE VILLAGE, Nev.-- PDL BioPharma Inc. said Tuesday it wants take Roche's Genentech business to arbitration over a royalty payment dispute. The company filed a notice with the American Arbitration Association in New Jersey.
June 11- Forest Laboratories Inc said on Tuesday it will add a representative of Carl Icahn as an independent member to its board, averting a new proxy battle with the billionaire investor. The specialty drugmaker said the appointment of Vincent Intrieri, 56, would expand the board's size to eleven from ten directors.